Related Experiment Video
Updated: Aug 3, 2025

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
Published on: November 2, 2013
Epigenetics regulation of prostate cancer: Biomarker and therapeutic potential
Ravindran Ragavi1, Panneerselvam Muthukumaran1, Srividhya Nandagopal1
1Department of Biochemistry, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India.
Abstract:
Prostate cancer (CaP) is the second leading cause of cancer death and displays a broad range of clinical behavior from relatively indolent to aggressive metastatic disease. The etiology of most cases of CaP is not understood completely, which makes it imperative to search for the molecular basis of CaP and markers for early diagnosis. Epigenetic modifications, including changes in DNA methylation patterns, histone modifications, miRNAs, and lncRNAs are key drivers of prostate tumorigenesis. These epigenetic defects might be due to deregulated expression of the epigenetic machinery, affecting the expression of several important genes like GSTP1, RASSF1, CDKN2, RARRES1, IGFBP3, RARB, TMPRSS2-ERG, ITGB4, AOX1, HHEX, WT1, HSPE, PLAU, FOXA1, ASC, GPX3, EZH2, LSD1, etc. In this review, we highlighted the most important epigenetic gene alterations and their variations as a diagnostic marker and target for therapeutic intervention of CaP in the future. Characterization of epigenetic changes involved in CaP is obscure and adequate validation studies are still required to corroborate the present results that would be the impending future of transforming basic research settings into clinical practice.
Related Concept Videos
Epigenetic Regulation
X-chromosome...
Mitogens and the Cell Cycle
Targeted Cancer Therapies
There are several types of targeted therapies against...
Abnormal Proliferation

